Scandinavian journal of urology · 2026
Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pedersen Torben Brøchner, Poulsen Charlotte Aaberg, Lund Martin, Albitar Maher, Østergaard Louise Dorner, Feddersen Søren, Lund Lars, Poulsen Mads Hvid
Аннотация
OBJECTIVE: This study aimed to compare test sensitivity for detecting aggressive prostate cancer and test specificity (measured by reduction in prostate biopsies) between algorithm-triage and standard systematic biopsy in elderly men with suspected prostate cancer.
METHODS: This randomised controlled trial enrolled men ≥ 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, integrated with clinical characteristics and PSA measurements to predict prostate cancer with International Society of Urological Pathology grade group ≥ 2. Patient-reported outcomes measures were collected using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores or subdomains throughout a 24-month follow-up.
CLINICALTRIALS: gov: NCT04079699.
RESULTS: A total of 202 men were included between October 2019 and September 2021. The study was terminated early due to algorithm underperformance. The algorithm-triage arm detected fewer indolent cancers (7.9% vs. 19%, absolute difference -10.9 percentage points, 95% confidence interval [CI]: -21.0 to -1.0 pp, P = 0.039) but also fewer clinically significant cancers (26% vs. 40%, absolute difference -13.9 percentage points, 95% CI: -27.6 to -0.1 pp, P = 0.051) compared to systematic biopsy. Patient-reported outcomes showed no significant between-group differences in FACT-P scores or subdomains throughout 24-month follow-up (differences 0.1-2.2 points, all P > 0.05), indicating comparable quality of life.
CONCLUSION: The biomarker-based algorithm-triage reduced biopsy numbers but also detected fewer -clinically significant prostate cancers. Quality of life was comparable between approaches.
METHODS: This randomised controlled trial enrolled men ≥ 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, integrated with clinical characteristics and PSA measurements to predict prostate cancer with International Society of Urological Pathology grade group ≥ 2. Patient-reported outcomes measures were collected using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores or subdomains throughout a 24-month follow-up.
CLINICALTRIALS: gov: NCT04079699.
RESULTS: A total of 202 men were included between October 2019 and September 2021. The study was terminated early due to algorithm underperformance. The algorithm-triage arm detected fewer indolent cancers (7.9% vs. 19%, absolute difference -10.9 percentage points, 95% confidence interval [CI]: -21.0 to -1.0 pp, P = 0.039) but also fewer clinically significant cancers (26% vs. 40%, absolute difference -13.9 percentage points, 95% CI: -27.6 to -0.1 pp, P = 0.051) compared to systematic biopsy. Patient-reported outcomes showed no significant between-group differences in FACT-P scores or subdomains throughout 24-month follow-up (differences 0.1-2.2 points, all P > 0.05), indicating comparable quality of life.
CONCLUSION: The biomarker-based algorithm-triage reduced biopsy numbers but also detected fewer -clinically significant prostate cancers. Quality of life was comparable between approaches.